Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8697389 | 0.82 | AKR1B1 (0.41) | PPIACYP1A2CYP2C9TSHRCYP2C19 | |
| SCHEMBL5818114 | 0.79 | CA1 (0.33) | PPIACYP1A2HDAC3HDAC4HDAC7 | |
| SCHEMBL5917355 | 0.77 | CA1 (0.32) | PPIACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL114462 | 0.76 | CA1 (0.35) | PPIACYP1A2CYP2D6MAPTFABP7 | |
| SCHEMBL1934600 | 0.76 | ALDH1A1 (0.40) | PPIACYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL5488253 | 0.76 | CA1 (0.37) | PPIA | |
| SCHEMBL45391 | 0.74 | HTR7 (0.36) | ALDH1A1KMT2A | |
| SCHEMBL1456494 | 0.74 | CA1 (0.33) | — | |
| SCHEMBL2877604 | 0.72 | PPIA (0.46) | PPIACYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL3165966 | 0.71 | TTR (0.35) | PPIACYP1A2TSHRHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | claimed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3898613-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
| EP-2940007-B1 | TYROSINE DERIVATIVE AND MANUFACTURING METHOD FOR TYROSINE DERIVATIVE | NARD INSTITUTE LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9533023-B2 | EIF4E binding peptides | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-01-03 | — | — | US | disclosed |
| EP-2569327-B1 | EIF4E BINDING PEPTIDES | AGENCY SCIENCE TECH & RES (SG) | 2016-05-25 | — | — | EP | disclosed |
| WO-2011136744-A1 | EIF4E BINDING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-11-03 | — | — | WO | disclosed |
| EP-2204383-A1 | Processes for preparing eptifibatide and pertinent intermediate compounds | Millennium Pharmaceuticals, Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100105609-A1 | Processes for Preparing Eptifibatide | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7674768-B2 | Processes for preparing eptifibatide | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1735345-B1 | PROCESSES FOR PREPARING EPTIFIBATIDE AND PERTINENT INTERMEDIATE COMPOUNDS | MILLENNIUM PHARM INC (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1735345-A2 | PROCESSES FOR PREPARING EPTIFIBATIDE AND PERTINENT INTERMEDIATE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060036071-A1 | Processes for preparing eptifibatide | MILLENNIUM PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | disclosed |
| WO-2005100381-A2 | PROCESSES FOR PREPARING EPTIFIBATIDE AND PERTINENT INTERMEDIATE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105609-A1 | Processes for Preparing Eptifibatide | PTMS, VIP, ENPP2 | PPIA 819/4885CYP1A2 4348/4885CYP2D6 2519/4885 |
| US-20060036071-A1 | Processes for preparing eptifibatide | PTMS, VIP, ENPP2 | PPIA 819/4885CYP1A2 4348/4885CYP2D6 2519/4885 |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | PPIA 1779/4885CYP1A2 1941/4885CYP2D6 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.